Brachial Plexopathy Following Rapid Weight Loss from Tirzepatide: A Case Report.
Pain Med Case Rep · 2026
Last updated 2026-07-22| Journal | Pain Med Case Rep, 2026 |
|---|---|
| Citations | 0 |
| Molecules | tirzepatide |
Abstract
BACKGROUND: Weight reduction and metabolic changes have been associated with the development of compressive peripheral neuropathies.
CASE REPORT: We present the case of a right-handed 60-year-old man who had a medical history of hypertension and hypercholesterolemia and developed neuromuscular symptoms after being treated with tirzepatide. During a 6-month course of tirzepatide use, the patient lost 60 pounds. However, the treatment was complicated by right-sided brachial plexopathy symptoms, including scapular pain, paresthesia, and progressive triceps weakness. Electromyography and nerve conduction studies confirmed denervation potentials at the right C5-C7 roots. Imaging studies were unremarkable. Symptoms persisted despite conservative interventions but improved gradually after the tirzepatide regimen was ended. At 2 months after the cessation, the patient's pain decreased from a 5/10 score to a score of one-2/10, and his strength improved. The follow-up EMG/NCV demonstrated the resolution of the denervation-caused changes.
CONCLUSION: This case highlights a possible association between the rapid weight loss caused by GLP-1 RAs and the development of brachial plexopathy. In this patient's case, the latter condition improved after his medication was discontinued.
Verbatim abstract via PubMed 42263282 ↗
Related research
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity.